SBP-15

Efficacy and safety of zoledronic acid for postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor. - SBP-15

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061210010

Enrollment

200

Registered

2021-06-07

Start date

2021-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ER positive early breast cancer aromatase inhibitors induced osteoporosis

Interventions

Treatment of AI induced osteoporosis by Bisphosphonate (Zoledronic acid hydrate 5mg/year div. >15min)

Treatment of AI induced osteoporosis by Bisphosphonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ER positive postmenopausal breast cancer patients Patients recieving AI (35mL/min Serum Ca>8.0 mg/dL Without dental treatment With informed consent

Exclusion criteria

Exclusion criteria: Metastatic breast cancer patients Allargy with bisphosphonate Renal disfunction Active other cancers Treated with bisphosphonate The medical doctor judged ineligible

Design outcomes

Primary

Measure	Time frame
3 years rate of bone density change	—

Secondary

Measure	Time frame
5 years rate of bone metastasis 5 years rate of desiese free survival Safety Rate of fructure of vertebral bone Rate of fructutre of non-vertrbral bone	—

Contacts

Public ContactShien Tadahiko

Okayama University Hospital

tshien@md.okayama-u.ac.jp+81-86-235-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026